Background: Appendiceal neuroendocrine neoplasms (ANEN) are mostly indolent tumours treated effectively with simple appendectomy. However, controversy exists regarding the necessity of oncologic right hemicolectomy (RH) in patients with histologic features suggestive of more aggressive disease. We assess the effects of current guidelines in selecting the surgical strategy (appendectomy or RH) for the management of ANEN. Methods/Aims: This is a retrospective review of all ANEN cases treated over a 14-year period at 3 referral centres and their management according to consensus guidelines of the European and the North American Neuroendocrine Tumor Societies (ENETS and NANETS, respectively). The operation performed, the tumour stage and grade, the extent of residual disease, and the follow-up outcomes were evaluated. Results: Of 14,850 patients who had appendectomies, 215 (1.45%) had histologically confirmed ANEN. Four patients had synchronous non-ANEN malignancies. One hundred and ninety-three patients had index appendectomy. Seventeen patients (7.9%) had lymph node metastases within the mesoappendix. Forty-nine patients underwent RH after appendectomy. The percentages of 30-day morbidity and mortality after RH were 2 and 0%, respectively. Twelve patients (24.5%) receiving completion RH were found to have lymph node metastases. Two patients had liver metastases, both of them synchronous. The median follow-up was 38.5 months (range 1-143). No patient developed disease recurrence. Five- and 10-year overall survival for all patients with ANEN as the only malignancy was both 99.05%. Conclusions: The current guidelines appear effective in identifying ANEN patients at risk of harbouring nodal disease, but they question the oncological relevance of ANEN lymph node metastases. RH might present an overtreatment for a number of patients with ANEN.

1.
Ellis L, Shale MJ, Coleman MP: Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010;105:2563-2569.
2.
Lawrence B, Gustafsson BI, Chan A, et al: The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1-18, vii.
3.
Boudreaux JP, Klimstra DS, Hassan MM, et al: The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors. Pancreas 2010;39:753-766.
4.
Hauso O, Gustafsson BI, Kidd M, et al: Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655-2664.
5.
Mullen JT, Savarese DMF: Carcinoid tumors of the appendix: a population-based study. J Surg Oncol 2011;104:41-44.
6.
SEER Data, 1973-2013. https://seer.cancer.gov/data/.
7.
Yao JC, Hassan M, Phan A, et al: One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
8.
Pape U-F, Niederle B, Costa F, et al: ENETS consensus guidelines for neuroendocrine neoplasms of the appendix (excluding goblet cell carcinomas). Neuroendocrinology 2016;103:144-152.
9.
Pape U-F, Perren A, Niederle B, et al: ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135-156.
10.
McGory ML, Maggard MA, Kang H, et al: Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 2005;48:2264-2271.
11.
Grozinsky-Glasberg S, Alexandraki KI, Barak D, et al: Current size criteria for the management of neuroendocrine tumors of the appendix: are they valid? Clinical experience and review of the literature. Neuroendocrinology 2013;98:31-37.
12.
Alexandraki KI, Kaltsas GA, Grozinsky-Glasberg S, et al: Appendiceal neuroendocrine neoplasms: diagnosis and management. Endocr Relat Cancer 2016;23:R27-R41.
13.
Bamboat ZM, Berger DL: Is right hemicolectomy for 2.0-cm appendiceal carcinoids justified? Arch Surg 2006;141:349-352; discussion 352.
14.
Rindi G, Klöppel G, Couvelard A, et al: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762.
15.
Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A: AJCC Cancer Staging Manual (ed7). Chicago, IL: Springer 2010.
16.
Dindo D, Demartines N, Clavien P-A: Classification of surgical complications: a new proposal with evaluation in a cohort of 6,336 patients and results of a survey. Ann Surg 2004;240:205-213.
17.
Alexandraki KI, Griniatsos J, Bramis KI, et al: Clinical value of right hemicolectomy for appendiceal carcinoids using pathologic criteria. J Endocrinol Invest 2011;34:255-259.
18.
O'Donnell ME, Carson J, Garstin WIH: Surgical treatment of malignant carcinoid tumours of the appendix. Int J Clin Pract 2007;61:431-437.
19.
Tchana-Sato V, Detry O, Polus M, et al: Carcinoid tumor of the appendix: a consecutive series from 1,237 appendectomies. World J Gastroenterol 2006;12:6699-6701.
20.
Roggo A, Wood WC, Ottinger LW: Carcinoid tumors of the appendix. Ann Surg 1993;217:385-390.
21.
Stinner B, Kisker O, Zielke A, et al: Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg 1996;20:183-188.
22.
Kleiman DA, Finnerty B, Beninato T, et al: Features associated with metastases among well-differentiated neuroendocrine (carcinoid) tumors of the appendix: the significance of small vessel invasion in addition to size. Dis Colon Rectum 2015;58:1137-1143.
23.
Moertel CG, Dockerty MB, Judd ES: Carcinoid tumors of the vermiform appendix. Cancer 1968;21:270-278.
24.
Moertel CG, Weiland LH, Nagorney DM, et al: Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987;317:1699-1701.
25.
Ciarrocchi A, Pietroletti R, Carlei F, et al: Propensity adjusted appraisal of the surgical strategy for appendiceal carcinoids. Tech Coloproctol 2015;19:35-41.
26.
de Lambert G, Lardy H, Martelli H, et al: Surgical management of neuroendocrine tumors of the appendix in children and adolescents: a retrospective French multicenter study of 114 cases. Pediatr Blood Cancer 2016;63:598-603.
27.
Steffen T, Ebinger SM, Warschkow R, et al: Long-term survival is not impaired after the complete resection of neuroendocrine tumors of the appendix. World J Surg 2015;39:2670-2676.
28.
Modlin IM, Frilling A, Salem RR, et al: Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery 2015;159:336-347.
29.
Modlin IM, Kidd M, Latich I, et al: Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Ann Surg 2006;244:52-60.
30.
Goede AC, Caplin ME, Winslet MC: Carcinoid tumour of the appendix. Br J Surg 2003;90:1317-1322.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.